Search
for
Sort by
Research 181–210 of 1000+
- The JAK/STAT signaling pathway: from bench to clinic
- <i>In vivo </i>CD44‐CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance
- Under Development JAK Inhibitors for Dermatologic Diseases
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- Advances in the mechanism and new therapies of alopecia areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Current Treatments for Alopecia Areata
- Answer
- JAK Inhibitors for Treatment of Alopecia Areata
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Baricitinib for the Treatment of Alopecia Areata
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Regulation of Involucrin Gene Expression
- Targeting of Smoothened for therapeutic gain
- Type II Keratins Are Phosphorylated on a Unique Motif during Stress and Mitosis in Tissues and Cultured Cells
- PKC downregulation upon rapamycin treatment attenuates mitochondrial disease
- Alopecia areata – Current understanding and management
- Mechanisms of autophagy and their implications in dermatological disorders
- Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study